Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate in Hand Osteoarthritis Refractory to Usual Treatments
NCT07501507Phase 3Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in erosive hand osteoarthritis (EHOA) comparing Methotrexate injectable with Placebo (2 arms). Primary endpoint: Structural lesion at 12 months. Started Sep 2026; status: recruiting.
02
Drugs
methotrexate
03
Conditions
erosive hand osteoarthritis (EHOA)
Beyond the preview
Go deeper on NCT07501507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07501507.